Chi G, et al. - Researchers undertook this investigation to assess the impact of betrixaban on the occurrence of deep vein thrombosis (DVT) and also the extent of thrombus and to assess the association of baseline D-dimer with subsequent thrombus burden. They found that treatment with extended-duration betrixaban vs enoxaparin led to attenuation in the number of venous segments with thrombosis at 35 to 42 days. In addition, among acutely ill medical patients who developed DVT despite receiving thromboprophylaxis, a positive D-dimer was found to be associated with a greater extent of thrombus burden.